Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Narrative) (Details)

v3.4.0.3
Significant Accounting Policies (Narrative) (Details)
shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 08, 2016
USD ($)
Jan. 31, 2010
right
Mar. 31, 2016
USD ($)
shares
Mar. 31, 2015
USD ($)
shares
Dec. 31, 2015
USD ($)
Aug. 31, 2014
USD ($)
Earnings (Loss) Per Share            
Common shares excluded from computation | shares     3.5 4.5    
Cash, Cash Equivalents and Short-term Investments            
Maturity period of cash and cash equivalents, maximum     3 months      
Maturity period of short term investments, minimum     3 months      
Inventory, Net [Abstract]            
Inventory write downs     $ 0 $ 0    
Goodwill and Other Identifiable Intangible Assets            
Finite-lived intangible asset, useful life     20 years      
Amortization expense     $ 2,500,000 600,000    
Impairment of goodwill     0 0    
Amortization Expense            
Amortization expense 2016     10,600,000      
Amortization expense 2017     10,700,000      
Amortization expense 2018     10,700,000      
Amortization expense 2019     10,700,000      
Amortization expense 2020     10,700,000      
Property and Equipment            
Depreciation     100,000 100,000    
Contingent Liabilities            
Purchase of commercial license rights     $ 92,855,000 0    
Revenue Recognition            
Restocking fee (percent)     20.00%      
Minimum            
Revenue Recognition            
Period when partner sales reports are received after end of quarter     30 days      
Maximum            
Revenue Recognition            
Period when partner sales reports are received after end of quarter     60 days      
Equipment | Minimum            
Property and Equipment            
Estimated useful life of assets     3 years      
Equipment | Maximum            
Property and Equipment            
Estimated useful life of assets     10 years      
OMT, Inc.            
Property, Plant and Equipment [Line Items]            
Goodwill acquired $ 60,800,000          
Finite-lived intangible assets $ 167,000,000          
Cydex Pharmaceuticals, Inc            
Contingent Liabilities            
Fair value of liability     $ 6,900,000   $ 9,500,000  
Contingent liability change in amount     200,000 1,200,000    
Cydex Pharmaceuticals, Inc | Revenue Sharing            
Contingent Liabilities            
Purchase of commercial license rights     2,800,000 3,200,000    
Metabasis Therapeutics            
Contingent Liabilities            
Fair value of liability     2,400,000   4,000,000  
Contingent liability change in amount     (1,100,000) 1,200,000    
Number of contingent value rights | right   4        
Number of contingent value rights per series of contingent value rights | right   1        
Number of contingent value rights issued for each share | right   4        
Contingent value rights, frequency of cash payment   6 months        
Contingent liability, cash payment     2,600,000 0    
Omthera Pharmaceuticals            
Milestone Payments            
Milestone payment received         0  
2019 convertible senior notes            
Convertible Debt            
Principal amount outstanding     245,000,000   $ 245,000,000  
2019 convertible senior notes | Senior Notes            
Convertible Debt            
Principal amount outstanding           $ 245,000,000.0
Interest rate           0.75%
Acquired in-process research and development            
Goodwill and Other Identifiable Intangible Assets            
Impairment of IPR&D     $ 0 $ 0